Influence of multi-drug transporter gene ABCG2 polymorphism (C421A)‎ in clinical out care in some Iraqi chronic myeloid leukemia patients treated with imatinib mesylate

Abstract EN

In CML patients, Imatinib Mesylate (IM) treatment is a good choiee with an excellent ciïicacy outcomc.

But unfortunatcly, a signifieant obstacle of IM résistance has emerged rclating to the gcnctic polymorphism in drug transporter genes such as ABCG2 which cffects the metabolism and pharmacokinetic IM.

This study investigate the influence of ABCG2 C421A SNP in IM responsc among some Iraqi CML Patients (71 patients : 43 Malc , 28 Fcmalc) aged between (20-70) years in chronic phase with positive Philadelphia (Ph) chromosome, including 11 ncwly diagnoscd , and 60 treated with standard dose IM (400mg) on frontlinc treatment, 30 of them were IM responsc and 30 rcsistancc to IM drug, on the other hand 25 apparcntly hcalthy individuals were includcd as control group.

Aftcr the patients were informed about the détails of the rcscarch, they were approved to takc samplcs of their blood for study , 3ml of pcriphcral blood was withdrawn from CML patients and control groups .

The frcqucncy of homozygous mutant genotype (AA) of SNPaAcgi C421Awas signifieant higher in IM résistant CML patients as compared to IM good responsc CML patients with (O.R= 1.309 and p < 0.01).

The SNP abcg2 C421A was found to contributc to the gcnctic susccptibility of CML when evaluated with hcalthy control subjccts.

These rcconnoitcring results give a rcasonablc cause to explore such SNPs to be used as a biomarker in prédiction the responsc to IM treatment beforc getting.